NOVARTIS INDIA LIMITED vs TORRENT PHARMACEUTICALS L
A side-by-side comparison of NOVARTIS INDIA LIMITED (NOVARTIND) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, TORRENT PHARMACEUTICALS L leads NOVARTIND vs TORNTPHARM on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation31
- Profitability22
- Growth02
- Size & financial health13
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
NOVARTIND takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
EvenHow efficiently each company turns capital and sales into profit. Higher is better.
Growth
TORNTPHARM takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
TORNTPHARM takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has reduced debt.", "Company is almost debt free."]
- − ["The company has delivered a poor sales growth of -1.46% over past five years.", "Company has a low return on equity of 11.9% over last 3 years.", "Earnings include an other income of Rs.36.9 Cr."]
- + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
- − ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.